Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

SYDNEY, Australia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced today that it has been invited to present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, Oct. 2, 2018, at the Sofitel Hotel in New York City.

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live via the following webcast link and a replay will be available via the investors & media section of the Company’s website.

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting: U.S. Investors:Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited+1 (917) 860-9404; [email protected]Garth Russell, LifeSci Advisors +1 (646) 876-3613; [email protected]

Australian Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2 8234 0105; [email protected]

You May Also Be Interested In

• Hunting PLC (“Hunting” or “the Company” or “the Group”) Results for the Six Months Ended 30 June 2026
• WISeKey Appoints Alexander Hirsch as Group Chief Marketing Officer to Coordinate Global Marketing Across the Group
• Results of the first tranche of AB Tewox bonds